Lawrence Kenyon Takes Over As CEO At Outlook Therapeutics

Outlook Therapeutics, Inc., a biopharmaceutical company that received regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma). LYTENAVA™ is the first ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (wet AMD) in adults. Today, the firm announced that Russell Trenary has resigned from his role as President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, who currently serves as Executive Vice President, Chief Financial Officer, and a member of the board of directors, has been named interim CEO.

Randy Thurman, the company’s executive chairman, said in a statement, “On behalf of our management team and board, I would like to thank Russ for his dedication and many contributions to the company and wish him the best in his future endeavours. We are pleased to have Larry lead Outlook Therapeutics during this transition period. We remain committed to our plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025 and to begin sales of LYTENAVA™ in Europe in the first half of calendar 2025.”

Kenyon has been with the company since September 2015 as CFO and Secretary, and he also served as CEO from August 2018 to July 2021. The company has enlisted an executive search firm to assist the board in finding a permanent CEO.